These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 16202848)

  • 1. The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension.
    Dreisbach AW; Japa S; Sigel A; Parenti MB; Hess AE; Srinouanprachanh SL; Rettie AE; Kim H; Farin FM; Hamm LL; Lertora JJ
    Am J Hypertens; 2005 Oct; 18(10):1276-81. PubMed ID: 16202848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension.
    King LM; Gainer JV; David GL; Dai D; Goldstein JA; Brown NJ; Zeldin DC
    Pharmacogenet Genomics; 2005 Jan; 15(1):7-13. PubMed ID: 15864120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study.
    Lee CR; North KE; Bray MS; Couper DJ; Heiss G; Zeldin DC
    Pharmacogenet Genomics; 2007 May; 17(5):349-58. PubMed ID: 17429317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated 14,15- epoxyeicosatrienoic acid by increasing of cytochrome P450 2C8, 2C9 and 2J2 and decreasing of soluble epoxide hydrolase associated with aggressiveness of human breast cancer.
    Wei X; Zhang D; Dou X; Niu N; Huang W; Bai J; Zhang G
    BMC Cancer; 2014 Nov; 14():841. PubMed ID: 25406731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms.
    Yasar U; Lundgren S; Eliasson E; Bennet A; Wiman B; de Faire U; Rane A
    Biochem Biophys Res Commun; 2002 Nov; 299(1):25-8. PubMed ID: 12435384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of CYP2C8, CYP2C9 and CYP2J2 gene polymorphisms with myocardial infarction in South Indian population.
    Arun Kumar AS; Kumar SS; Umamaheswaran G; Kesavan R; Balachandar J; Adithan C
    Pharmacol Rep; 2015 Feb; 67(1):97-101. PubMed ID: 25560582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population.
    Hilli J; Rane A; Lundgren S; Bertilsson L; Laine K
    Fundam Clin Pharmacol; 2007 Aug; 21(4):379-86. PubMed ID: 17635176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians.
    Suarez-Kurtz G; Genro JP; de Moraes MO; Ojopi EB; Pena SD; Perini JA; Ribeiro-dos-Santos A; Romano-Silva MA; Santana I; Struchiner CJ
    Pharmacogenomics J; 2012 Jun; 12(3):267-76. PubMed ID: 21173785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variation in the cytochrome P450 epoxygenase pathway and cardiovascular disease risk.
    Theken KN; Lee CR
    Pharmacogenomics; 2007 Oct; 8(10):1369-83. PubMed ID: 17979511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population.
    Kudzi W; Dodoo AN; Mills JJ
    BMC Med Genet; 2009 Dec; 10():124. PubMed ID: 19954515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues.
    Enayetallah AE; French RA; Thibodeau MS; Grant DF
    J Histochem Cytochem; 2004 Apr; 52(4):447-54. PubMed ID: 15033996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice.
    Deng Y; Edin ML; Theken KN; Schuck RN; Flake GP; Kannon MA; DeGraff LM; Lih FB; Foley J; Bradbury JA; Graves JP; Tomer KB; Falck JR; Zeldin DC; Lee CR
    FASEB J; 2011 Feb; 25(2):703-13. PubMed ID: 21059750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution of soluble epoxide hydrolase, cytochrome P450 2C8, 2C9 and 2J2 in human malignant neoplasms.
    Enayetallah AE; French RA; Grant DF
    J Mol Histol; 2006 May; 37(3-4):133-41. PubMed ID: 16957870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing warfarin dose requirements in African-Americans.
    Momary KM; Shapiro NL; Viana MA; Nutescu EA; Helgason CM; Cavallari LH
    Pharmacogenomics; 2007 Nov; 8(11):1535-44. PubMed ID: 18034618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues.
    Delozier TC; Kissling GE; Coulter SJ; Dai D; Foley JF; Bradbury JA; Murphy E; Steenbergen C; Zeldin DC; Goldstein JA
    Drug Metab Dispos; 2007 Apr; 35(4):682-8. PubMed ID: 17220242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New genetic variant that might improve warfarin dose prediction in African Americans.
    Schelleman H; Brensinger CM; Chen J; Finkelman BS; Rieder MJ; Kimmel SE
    Br J Clin Pharmacol; 2010 Sep; 70(3):393-9. PubMed ID: 20716240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations.
    Pedersen RS; Brasch-Andersen C; Sim SC; Bergmann TK; Halling J; Petersen MS; Weihe P; Edvardsen H; Kristensen VN; Brøsen K; Ingelman-Sundberg M
    Eur J Clin Pharmacol; 2010 Dec; 66(12):1199-205. PubMed ID: 20665013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes at the CYP2C locus and disruption of CYP2C8/9 linkage disequilibrium in patients with essential tremor.
    Martínez C; García-Martín E; Alonso-Navarro H; Jiménez-Jiménez FJ; Benito-León J; García-Ferrer I; Vázquez-Torres P; Puertas I; Zurdo JM; López-Alburquerque T; Agúndez JA
    Neuromolecular Med; 2007; 9(2):195-204. PubMed ID: 17627038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers.
    Dorado P; Cavaco I; Cáceres MC; Piedade R; Ribeiro V; Llerena A
    Eur J Clin Pharmacol; 2008 Oct; 64(10):967-70. PubMed ID: 18548238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin.
    Tabrizi AR; Zehnbauer BA; Borecki IB; McGrath SD; Buchman TG; Freeman BD
    J Am Coll Surg; 2002 Mar; 194(3):267-73. PubMed ID: 11893129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.